Race Oncology Limited (ASX:RAC)
Race Oncology Limited (ASX:RAC) is a precision oncology company with a Phase II/III cancer drug called Bisantrene.
Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the driver of a range of different types of cancer.
RAC is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.
RAC also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.